Fines of nearly €150 million imposed on pharmaceutical company Lundbeck and a number of generic rivals by the European Commission have been upheld by the EU General Court. The Court's decisions are the first to find that pay-for-delay agreements breach EU antitrust rules
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the Danish company’s injunction application